The antibacterial and anti-biofilm effects of novel synthetized nitroimidazole compounds against methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli and Klebsiella pneumonia in vitro and in silico Authors: Elham Zarenezhad, Esmaeil Behmard, Raziyeh Karami, Somayeh Behrouz, Mahrokh Marzi, Abdolmajid Ghasemian, Mohammad Navid Soltani Rad Published: 2024 ABSTRACT AbstractThe antibiotic resistance and biofilm formation by bacterial pathogens has led to failure in infections elimination. This study aimed to assess the antibacterial and anti-biofilm properties of novel synthesized nitroimidazole compounds (8a–8o). In this study, nitroimidazole compounds were synthesized via the A3 coupling reaction of sample substrates in the presence of copper-doped silica cuprous sulfate (CDSCS). Fifteen and two carbapenemase producing Escherichia coli and Klebsiella pneumonia (CP-E. coli and CP-K. pneumonia, respectively) and one methicillin-resistant Staphylococcus aureus (MRSA) and one methicillin-susceptible S. aureus (MSSA) plus standard strain of each isolate were included. The antibacterial effects of these compounds demonstrated that the lowest minimum inhibitory and bactericidal concentrations (MIC/MBC, respectively) levels corresponded to compound 8g against S. aureus (1/2 µg/mL) and K. pneumonia (8/32 µg/mL) standard and clinical strains and confirmed by in silico assessment. This was comparable to those of metronidazole being 32–128 µg/mL against K. pneumonia and 32–64 µg/mL against S. aureus. In comparison to metronidazole, against CP-E. coli, compounds 8i and 8m had significantly higher antibacterial effects (p < 0.001) and against CP-K. pneumonia, compounds 8a–8j and 8l–8o had significantly higher (p < 0.0001) antibacterial effects. Compound 8g exhibited significantly higher antibacterial effects against MSSA and compounds 8b (p < 0.001), 8c (p < 0.001), 8d (p < 0.001), 8e (p < 0.001) and 8g (p < 0.0001) exerted significantly higher antibacterial effects than metronidazole against MRSA. Moreover, potential anti-biofilm effects was corresponded to compounds 8a, 8b, 8c, 8e, 8f, 8g, 8i, 8k, 8m and 8n. Considering the antibacterial and anti-biofilm effects of novel synthesized compounds evaluated in this study, further assessments is warranted to verify their properties in vivo and clinical trials in the future.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13065-024-01333-w.Keywords: Antibiotic resistance, Biofilms, Methicillin-resistant Staphylococcus aureus, Carbapenem resistance, Nitroimidazole compounds Introduction Antibiotic resistance is a growing global health threat resulting in increased morbidity, mortality and healthcare costs [1, 2]. According to the World Health Organization (WHO), antibiotic resistance is a current leading global threat to health, food security, and development. The indiscriminate and uncontrolled consumption of antibiotics and long-term hospital residence include the primary drivers of antibiotic resistance [3–5]. In these conditions of antibiotics frequent or incorrect utilization, bacterial strains develop various mechanisms of resistance [6, 7]. This also leads to failure in infections eradication, longer hospital stays and higher healthcare costs [8, 9]. If current trends continue, this number could rise to millions of deaths annually by 2050 [10, 11] and pose cost to the global economy up to $100 trillion by 2050 which includes costs associated with increased healthcare spending, lost productivity, and premature death [12, 13]. Carbapenemases are enzymes produced by those Gram-negative bacteria exhibiting resistance to carbapenems via hydrolyzing their β-lactam rings [14, 15]. Enterobacteriaceae family members such as Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) are among species with this ability causing serious infections such as urinary tract, bloodstream, and gastrointestinal infections and pneumonia [16–18]. Carbapenem-resistant Enterobacteriaceae (CRE) are a significant public health threat due to vast resistance phenotype [19–21]. Considering these problems, the development of novel antibiotics, accurate infection prevention and control measures, surveillance to monitor the prevalence and spread of carbapenemase-bearing strains and the appropriate utilization of antibiotics are crucial [22, 23]. Staphylococcus aureus (S. aureus) is a ubiquitous bacterium among which MRSA (Methicillin-resistant Staphylococcus aureus) strains have acquired a novel penicillin-binding protein (PBP) known as PBP-2a [24]. These strains have developed resistance to several antibiotics, including methicillin and other beta-lactam antibiotics [25–28]. One of the most important bioactive N-heterocyles for drug discovery are imidazole compounds and especially nitroimidazole derivatives (NIM). 5-nitroimidazole derivatives [29] including metronidazole (2-Methyl-5-nitroimidazole-1-ethanol), ornidazole (α-(Chloromethyl)-2-methyl-5-nitroimidazole-1-ethanol) and tinidazole (1-[2-(Ethylsulfonyl) ethyl]-2-methyl-5-imidazole) [30] are widely utilized to control diseases caused by protozoan and anaerobic bacterial infections (Fig. 1). Also, 2-methyl-5-nitroimidazole derivatives have been used as antibacterial factors for a long time due to their therapeutic effect [31]. Antimicrobial effects of imidazole, oxadiazole, benzimidazole and thiazole-based schiff containing compounds have been also demonstrated [32–35]. However, nitroheterocyclic compounds have other biological activities [30] like antituberculosis and antifungal activities [31]. Metronidazole (2-methyl-5-nitroimidazole) is a synthetic derivative of azomycin with strong antibacterial and antiparasitic activities that was originally identified in cultures of Streptomyces species in the 1950s [36]. The azomycin (2-nitroimidazole) was the only accepted nitroimidazole relying antibiotic developed using Actinobacteria (Streptomyces eurocidicus and Nocardia mesenterica) and Proteobacteria (Pseudomonas fluorescens) [37]. Metronidazole (MTZ), secnidazole, tinidazole, ornidazole, satranidazole, benznidazole, pretomanid, delamanid, megazol and fexinidazole are nitroimidazoles derived from azomycin, used to treat infections caused by anaerobic Gram-positive and Gram-negative bacteria [38–40] (Fig. 1). Metronidazole acts as an antibacterial from the start because it lacks any toxicity (different from other nitroheterocycles) [41]. In general, a reactive intermediate created in the microbial reduction of the 5-nitro group of nitroimidazoles covalently binds to the microorganism's DNA and causes a lethal efficacy [41]. The objective of this study was the assessment of antibacterial and anti-biofilm effects of novel synthetized nitroimidazole compounds. Structure of nitroimidazole-based drugs for the treatment of infections caused by drug-resistant bacteria [38] Methodology General All chemicals were directly applied without any additional purifications after being bought from Merck or other chemical suppliers. Certain synthetic techniques were used to create copper-doped silica cuprous sulfate (CDSCS) [42], propargyl p-toluenesulfonate (3), and 2-methyl-5-nitro-1-prop-2-ynyl-1H-imidazole (5) [43]. Thin-layer chromatography (TLC) was used to track reactions utilizing SILG/UV 254 silica-gel plates. The purifications was performed using column chromatography silica gel 60 (0.063–0.200 mm, 70–230 mesh; ASTM). Open capillary tubes were used to measure melting points utilizing an Electrothermal IA 9000. The elemental analyses, GC/MS, and IR spectra were obtained using the Perkine-Elmer 240-B micro-analyzer, Shimadzu GC/MS-QP 1000-EX equipment (m/z; rel.%), and Shimadzu FT-IR-8300 spectrophotometer, respectively. Using a Brüker Avance-DPX-300 spectrometer running at 300/75 MHz, the 1H and 13C NMR spectra were acquired. Coupling constants J are given in Hz, and chemical shifts are given in ẟ with respect to tetramethylsilane (TMS) as an internal reference [44]. Compounds 8a–8o synthesis The ingredients including toluene, CDSCS (0.05 mol%, 0.3 g) and 10 mmol of each alkyne 5, intended cyclic amine 7 and aldehyde 6 were mixed in a flask (double-necked round bottom, 100 mL) with a condenser and heated to reflux, where TLC was used to track the reaction's development. After over 11–15 h, as shown in Table 2, TLC monitoring showed no additional improvement in the reaction progress, at which point the CDSCS was separated using a fritted glass and washed with hot EtOAc. The filtrate was then concentrated under vacuum, and the residual material was dissolved in 100 mL of CHCl3 and washed with water (2 × 100 mL). After that, the organic layer was dried (Na2SO4) and concentrated to produce the crude product, which was then purified using appropriate elution on a short column chromatography [44]. Table 2Influence of various reaction parametersEntrySolventCatalyst/mol%T (°C)Time (h)Yielda (%)1CDSCS/0.0510012392H2Or.t24Trace37024174Reflux14215THF11456CHCl315627MeCN14568EtOH11359DMF110125110TolueneToluene7016781190148312Reflux119013–24NR14CDSCS/0.02245215CDSCS/0.03187016CDSCS/0.04148417CDSCS/0.06119018CuCl/0.05157119CuI/0.05157320Cu2O/0.05155921Cu(OAc)2/0.05157022CuSO4.5H2O/0.051564a Isolated yieldNR: No reaction Influence of various reaction parameters Toluene Toluene a Isolated yield NR: No reaction Bacterial isolates Bacterial standard strains included Escherichia coli ATCC25922, Staphylococcus aureus ATCC25923 and Klebsiella pneumonia ATCC13883. Besides, clinical isolates included 15 carbapenemase producer E. coli (CP-E. coli), two CP-K. pneumonia, one methicillin-susceptible S. aureus (MSSA) and one methicillin-resistant S. aureus (MRSA) isolates. The MRSA was determined using cefoxitin (30 μg) disk resistance in disk diffusion method. The ESBL production was confirmed through ceftazidime (30 µg/mL) and/or cefotaxime (30 µg/mL) resistance and synergy test between co-amoxiclav and ceftazidime/cefotaxime disks (Liofilchem, Rosetodegli Abruzzi, Italy). The carbapenemase production was determined using the combined disk (meropenem plus phenyl boronic acid and meropenem plus dipicolinic acid, Liofilchem, Rosetodegli Abruzzi, Italy) and CARBA-NP tests. The susceptibility tests were implemented according to the clinical laboratory and standards institute (CLSI) M100 version 2021 [45, 46]. Antibiotic resistance profile The profile of antibiotic resistance among bacterial isolates was determined using the disk diffusion (Kirby Bauer) or VITEK2 compact system method according to the CLSI (clinical and laboratory standards institute) version 2023 [47]. Pseudomonas aeruginosa (ATCC27853), E. coli (ATCC25922) and K. pneumoniae (ATCC700603) were used as the control for verifying disks quality. Minimum inhibitory concentration and minimum bactericidal concentration The minimum inhibitory concentration (MIC) levels of synthetic compounds against standard and clinical bacterial isolates were determined using broth micro-dilution method in 96-well plates as per the CLSI protocol, version 2021. The bacterial suspension turbidity was equal to the half McFarland concentration. The materials range included 0.5–1024 µg/mL. The serial dilution was implemented using Mueller Hinton broth (MHB, Merck, Germany) medium (100 µL) (supplemented by 20–25 mg/L of calcium and 10–12.5 mg/L of magnesium) plus 90 µL of compounds and 10 µL of bacterial suspension. The minimum bactericidal concentration (MBC) was determined by spot culture of 50 µL of those wells or dilutions contents without bacterial growth onto the Mueller Hinton agar (MHA) medium (Merck, Germany). Acetic acid (0.5%) and gentamicin were used as the negative and positive control of the antibacterial tests, respectively. Biofilm formation Biofilm formation was accomplished using microtiter tissue plate assay into 96-well plates in triplicate for each bacterial isolate. Bacterial suspension (20 µL of 106 CFU/mL) was added to each well containing trypticase soy broth (TSB, 180 µL; Merck, Germany) and incubated at 37 °C for 24 h. For those isolates exposed to synthetic compounds, the initial cultures were incubated for 5 h and then the wells content was replaced by 32 µg/mL and 64 µg/mL of compounds concentrations into the TSB medium and incubated for 24 h. Next, the plates were washed three times using double distilled H2O (ddH2O) and the wells contents were fixed using 150 µL of methanol. The wells were dried and 0.1% of crystal violet (for Gram-negative bacteria) and safranin (for Gram-positive bacteria) were added and washed after 15 min. The wells contents were solved into 96% ethanol and each turbidity was read using enzyme linked immunosorbent assay (ELISA) reader at 490 nm wavelength. The biofilm formation level for each test was calculated using following formula provided in Table 1. A strong biofilm-producer S. aureus isolate was used as positive control for the biofilm formation. Table 1Biofilm formation level calculationBiofilm formation abilityCalculation of cut-off levelOD calculated resultsStrongOD > ODc4< 0.33296 ModerateODc2 ≤ OD < ODc40.33296 ≤ 0.16648 < ODWeakODc ≤ OD < 2ODc0.16648 ≤ 0.083324 < ODNo bindingOD ≤ ODc0.08324 ≤ ODOD: optical density, ODc: mean OD of control wells Biofilm formation level calculation OD: optical density, ODc: mean OD of control wells The in silico analyses The in silico assessment of the binding stability of compound 8g to the PBP2a of MRSA was implemented to verify experimental results. Firstly, the three-dimensional structure of PBP2a (PDB ID: 6H5O) was obtained from the Protein Data Bank (PDB). The AutoDockFR program was used to prepare the protein for molecular docking [48]. The ligands were processed using the OpenBabel program to add hydrogen atoms and generate a 3D structure in PDB format. A grid box size of 18.5 Å × 17.0 Å × 18.5 Å was selected to surround the catalytic site of PBP2a, which included residues E402, S403, K406, Y446, E447, S462, N464, K597, S598, and T600. The AutoDock Vina tool was utilized for conducting docking studies with the PBP2a structures and ligands in PDBQT format. Each docked complex 3D structure was analyzed using PyMOL visualization tool. In order to estimate the stability of a complex system and study its structural flexibility, molecular dynamics (MD) simulations were conducted using GROMACS version 2022 [49, 50]. The protein molecule was parameterized using the OPLS all-atom (OPLS-AA) force field [51]. The protein–ligand complex was then placed in a simulation box and solvated with TIP3P solvent molecules [52]. The system was neutralized by adding 0.15 mol/L Na+/Cl− ions. The energy of the system was minimized using the steepest descent algorithm. The system was equilibrated using NVT and NPT ensembles with a time of 0.5 ns each, utilizing a V-rescale Berendsen thermostat and a Parrinello-Rahman barostat. The temperature of the system was gradually increased from 0 to 310 K, with the pressure set to 1 atm for the NPT ensemble. The particle-mesh Ewald (PME) and LINCS algorithms were used to calculate electrostatic interactions and restrain bond lengths in the protein, respectively [53, 54]. Periodic boundary conditions were applied during the simulation. The final coordinates of the complex system were analyzed using standard MD analyses. The final conformation of the protein–ligand complex was selected from the MD trajectory and visualized using PyMOL and LIGPLOT software. Additionally, the MMPBSA method was employed to calculate the binding free energy considering this formula: ΔGbind = Gcomplex − (Gprotein + Gligand) [55]. The ADMET (Adsorption, distribution, metabolism, excretion and toxicity) properties of potential candidate compound 8g was also evaluated using pk/CSM web server. Data analysis The data was analyzed using Graph Pad Prism version 8, from which Chi-Square and analysis of variance (ANOVA) tests were applied for determination of differences at p value cut off of 0.05. Results Chemistry According to the routes shown in Scheme 1, the synthesis of the designated compounds was carried out. In this synthesis pathway, 1, 2-methyl-5-nitro-1-prop-2-ynyl-1H-imidazole 5 was operated as an effective alkyne to prepare compounds 8a–8o. The first step of this synthetic process contains the tosylation of Propargyl alcohol 1 to obtain prop-2-yn-1-yl 4-methylbenzenesulfonate (3) as a yellow oil [43, 56]. In the second step, 5-nitro isomer of 5 was obtained from the reaction between N-propargylation of 2-methyl-5-nitro-imidazole 4 with 3 under solvent-free condition [43, 57]. In other words, alkyne 5 was produced by coupling compound 4 with a propargylating factor. For this purpose, the usage of propargyl p-toluenesulfonate 3 would rather over propargyl bromide due to its safety, inexpensiveness and comfortable synthesis using tosylation of propargyl alcohol. Eventually, the A3 coupling reaction between terminal alkyne 5, aldehydes 6, and cyclic amines 7 was carried out by copper-doped silica cuprous sulfate (CDSCS) to synthesize new derivative of 2-methyl-5-nitroimidazole propargylamines. In the following, the effect of various parameters including temperature, solvent, and catalyst amount was explored on reaction between terminal alkyne 5, benzaldehyde, and morpholine in the attendance of CDSCS to afford 4-(4-(2-methyl- 5-nitro-1H-imidazole-1-yl)-1-phenylbut-2-ynyl) morpholine (8a) to achieve optimal condition for effective synthesis of 8a–8o (Table 2). Synthetic pathway for new 2-methyl-5-nitroimidazole compounds 8 According to the principle of green chemistry in doing the reaction in solvent-free conditions, the sample reaction was firstly performed in the solvent-free system. According to Table 2, the entry 1 of compound 8a was achieved in 39% after 12 h. Thereafter, it was tried to react the sample in water and increase the reaction efficiency by increasing the temperature from room temperature to reflux. As entry 2–4 had no acceptable results, several polar and nonpolar solvents were applied. The highest yield of compound 8a was obtained in toluene (entry 12). Entries 5–9 outlined yields from other solvents like THF, CHCl3, MeCN, EtOH, and DMF giving 35–62% yields of sample compound. Consequently, toluene was used as a selective solvent for the synthesis of the defined compounds by the existing protocol. Then, the effect of temperature on the reaction progress was investigated (entries 10–12) (Table 2). As seen in entry 12, the reaction efficiency was improved with increasing temperature, and the best outcome in toluene recovery was acquired. Considering the focus on optimizing the catalyst loading to improve and develop the reaction yield (Table 2, entries 10 and 13–17), no product was determined in the lack of CDSCS, highlighting the catalyst role in the reaction development (entry 13). Accordingly, the reaction efficiency increased at higher levels of CDSCS up to 0.05 mol% (entry 10), while further increase in the catalyst amount had no acceptable result. As a result, 0.05 mol% of CDSCS in refluxing toluene was considered as the optimal condition for the synthesis of all products. To better understand the catalytic activity and power of CDSCS, the reaction of sample A3 coupling was carried out in the presence of some copper salts available as catalysts in reflux toluene (Table 2, entries 10 and 18–22). For 8a compound synthesis, catalysts CuCl, CuI, Cu2O, Cu (OAc)2, and CuSO4.5H2O had 59–73% efficiency following 15 h, while, CDSCS yielded 90% efficacy following 11 h. Moreover, the oxidation state of copper exerted no meaningful effect on the rapidity and efficiency of the reaction. Other derivatives 8a–8o were synthesized after achieving optimal reaction conditions (Table 3). For this purpose, alkyne 5, various aldehydes 6 and cyclic amines 7 were subjected to the A3 coupling reaction in the presence of CDSCS in reflux toluene for specified times. Four aromatic aldehydes including benzaldehyde, 4-chlorobenzaldehyde, 2,4-dichlorobenzaldehyde, and 2-chlorobenzaldehyde, and also four cyclic amines containing morpholine, 1-phenylpiperazine, 1-benzylpiperazine, and 4-benzylpiperidine were used for the synthesis of listed compounds. These aromatic aldehydes and cyclic amines were chosen due to the abundance of these parts in known drugs and active pharmaceutical compounds [58]. Considering the heterogeneous nature of CDSCS, hot filtration test was conducted to ensure the entire or adequate leaching of dissolved Cu(I) into the filtrate to continue a homogeneous reaction after solid catalyst removal [59]. The improvement of the reaction was confirmed using Gas Chromatography (GC) analysis, inferring that no additional 8a was obtained even after 24 h. The catalytic activity was studied for 7 successive runs for the synthesis of 8a under optimal reaction conditions to evaluate the reusability of CDSCS. For this purpose, the isolated CDSCS was washed with hot ethyl acetate and dried for 30 min at 100 °C in a vacuum oven. The recycled CDSCS was then reused in the synthesis of 8a without addition or charge of fresh CDSCS to the reaction mixture. According to Inductively Coupled Plasma (ICP) analysis, 0.01% Cu was eluted from CDSCS after seven repetitions, highlighting thermal and chemical stability of the catalyst under optimal reaction conditions. Table 3Isolated structures and yields of synthesized compounds 8a–8o Isolated structures and yields of synthesized compounds 8a–8o In Scheme 2, a possible mechanism has been inferred for the synthesis of compounds 8a by the A3 coupling reaction of sample substrates in the presence of CDSCS [60]. Initially, the C-H activation of alkyne 7 with the nanocatalyst forms the π-alkyne complex I, which is converted to the copper acetylide adduct III. At the same time, the condensation of benzaldehyde with morpholine leads to the in situ production of iminium ion II. Finally, compounds 8a is generated by nucleophilic addition of adduct III to iminium ion II, and regenerated the catalyst for subsequent catalytic run. After the compounds synthesis, they were dissolved into 0.5% acetic acid. Synthesis mechanism of 8a in the presence of CDSCS NMR Data of synthesized compounds The NMR data of synthesized compounds has been included below and in the supplementary data file as previously determined [44]. 4-(4-(2-methyl-5-nitro-1H-imidazole-1-yl)-1-phenylbut-2-ynyl) morpholine (8a) Column Chromatography (SiO2) eluted with n-hexane:EtOAc (1:2) afforded pure product as white solid (3.06 g, 90%); m. p, 153e155 °C. IR (KBr): 3100, 2954, 2169, 1671, 1560, 1485, 1352 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.49–2.51 (complex, 7H, CH3, 2 NCH2), 3.68–3.71 (m, 4H, 2OCH2), 4.59 (s, 1H, NCH), 4.84 (s, 2H, NCH2C≡C), 7.26–7.38 (m, 3H, aryl), 7.45–7.47 (m, 2H, aryl), 7.89 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 14.30, 26.61, 49.72, 60.23, 66.55, 81.86, 84.56, 127.21, 128.42, 128.95, 131.74, 138.03, 139.85, 151.85. MS (EI): m/z (%) = 340 (21.5) [M+]. Anal. Calc. for C18H20N4O3: C, 63.52; H, 5.92; N, 16.46; found: C, 63.70; H, 6.08; N, 16.61. 4-(1-(4-chlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl) but-2-ynyl) morpholine (8b) Column Chromatography (SiO2) eluted with n-hexane:EtOAc (1) afforded pure product as white solid (3.33 g, 89%); m. p,171–173 °C. IR (KBr): 3068, 2950, 2180, 1678, 1552, 1481, 1350, 1125 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.47–2.59 (complex, 7H, CH3, 2 NCH2), 3.68–3.71 (m, 4H, 2OCH2), 4.58 (s, 1H, NCH), 4.85 (s, 2H, NCH2C≡C), 7.24–7.28 (m, 1H, aryl), 7.31–7.34 (m, 1H, aryl), 7.40–7.43 (m, 2H, aryl), 7.89 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.75, 26.72, 49.89, 58.83, 66.22, 82.28, 85.07, 128.60, 130.48, 131.69, 132.94, 138.21, 151.80. MS (EI): m/z (%) = 374 (23.8) [M+]. Anal. Calc. for C18H19ClN4O3: C, 57.68; H, 5.11; N, 14.95; found: C, 57.95; H, 5.26; N, 15.09. 4-(1-(2,4-dichlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl)but-2-ynyl)morpholine (8c) Column Chromatography (SiO2) eluted with n-hexane:EtOAc (2:5) afforded pure product as white solid (3.51 g, 86%); m. p, 143–145 °C. IR (KBr): 3070, 2973, 2148, 1676, 1556, 1459, 1354, 1128 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.48–2.54 (complex, 7H, CH3, 2NCH2), 3.64–3.68 (m, 4H, 2OCH2), 4.82 (s, 2H, NCH2C≡C), 4.87 (s, 1H, NCH), 7.24–7.27 (m, 1H, aryl), 7.42–7.47 (m, 2H, aryl), 7.83 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.70, 26.64, 49.79, 51.94, 66.15, 81.86, 84.95, 126.59, 129.97, 131.53, 131.83, 134.29, 134.91, 135.85, 138.30, 151.86. MS (EI): m/z (%) = 408 (27.9) [M+]. Anal. Calc. for C18H18Cl2N4O3: C, 52.82; H, 4.43; N, 13.69; found: C, 52.98; H, 4.57; N, 13.83. 4-(1-(2-chlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl) but-2-ynyl) morpholine (8d) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as creamy solid (3.07 g, 82%); m. p, 169–171 °C. IR (KBr): 3037, 2965, 2193, 1690, 1568, 1463, 1357, 1140 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.45 (s, 3H, CH3), 2.51 (br s, 4H, 2NCH2), 3.57–3.69 (m, 4H, 2OCH2), 4.82 (s, 2H, NCH2C≡C), 4.91 (s, 1H, NCH), 7.11–7.25 (m, 2H, aryl), 7.34–7.38 (m, 1H, aryl), 7.48–7.51 (m, 1H, aryl), 7.85 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 14.20, 26.18, 49.78, 51.74, 66.40, 81.70, 84.70, 126.56, 128.62, 128.91, 129.91, 131.90, 134.25, 136.88, 138.22, 151.86. MS (EI): m/z (%) = 374 (19.6) [M+]. Anal. Calc. for C18H19ClN4O3: C, 57.68; H, 5.11; N, 14.95; found: C, 57.45; H, 5.26; N, 14.80. 1-(4-(2-methyl-5-nitro-1H-imidazole-1-yl)-1-phenylbut-2-ynyl)-4-phenylpiperazine (8e) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as bright brown solid (3.65 g, 88%); m. p, 181–183 °C. IR (KBr): 3055, 2947, 2186, 1680, 1554, 1479, 1350 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.48 (s, 3H, CH3), 2.67 (br s, 4H, 2NCH2), 3.18 (br s, 4H, 2PhNCH2), 4.67 (s, 1H, NCH), 4.78 (s, 2H, NCH2C≡C), 6.75–6.91 (m, 3H, aryl), 7.16–7.39 (m, 5H, aryl), 7.48 (d, J = 7.5 Hz, 2H, aryl), 7.86 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.93, 26.70, 48.60, 49.57, 60.71, 82.00, 85.59, 114.37, 118.29, 127.47, 128.45, 128.76, 129.75, 131.71, 138.25, 139.87, 149.71, 151.66. MS (EI): m/z (%) = 415 (21.6) [M+]. Anal. Calc. for C24H25N5O2: C, 69.38; H, 6.06; N, 16.86; found: C, 69.53; H, 6.19; N, 17.02. 1-(1-(4-chlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl)but-2-ynyl)-4-phenylpiperazine (8f) Column Chromatography (SiO2) eluted with n-hexane:EtOAc (1:2) afforded pure product as bright brown solid (3.82 g, 85%); m. p, 201–203 °C. IR (KBr): 3027, 2930, 2129, 1677, 1553, 1426, 1347, 1160 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.49 (s, 3H, CH3), 2.55–2.70 (m, 4H, 2NCH2), 3.13–3.22 (m, 4H, 2PhNCH2), 4.68 (s, 1H, NCH), 4.84 (s, 2H, NCH2C≡C), 6.80–6.91 (m, 3H, aryl), 7.20–7.28 (m, 4H, aryl), 7.32–7.46 (m, 2H, aryl), 7.85 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.59, 26.18, 48.39, 49.95, 60.61, 82.05, 85.89, 114.96, 119.18, 128.40, 128.73, 129.50, 131.81, 132.57, 138.32, 139.81, 149.39, 151.69. MS (EI): m/z (%) = 449 (18.7) [M+]. Anal. Calc. for C24H24ClN5O2: C, 64.07; H, 5.38; N, 15.57; found: C, 64.29; H, 5.56; N, 15.74. 1-(1-(2,4-dichlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl)but-2-ynyl)-4-phenylpiperazine (8g) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as bright brown solid (4.02 g, 83%); m. p, 157–159 °C. IR (KBr): 3084, 2938, 2170, 1688, 1558, 1448, 1353, 1161 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.46 (s, 3H, CH3), 2.69–2.70 (m, 4H, 2NCH2), 3.10 3.20 (m, 4H, 2PhNCH2), 4.82 (s, 2H, NCH2C≡C), 4.96 (s, 1H, NCH), 6.79–6.90 (m, 3H, aryl), 7.22–7.29 (m, 3H, aryl), 7.39 (s, 1H, aryl), 7.48 (d, J = 8.1 Hz, 1H, aryl), 7.82 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.32, 27.02, 48.76, 49.96, 52.37, 83.77, 87.81, 114.37, 118.79, 126.83, 129.71, 130.02, 131.30, 131.70, 134.09, 134.91, 135.69, 138.10, 149.80, 151.78. MS (EI): m/z (%) = 483 (22.6) [M+]. Anal. Calc. for C24H23Cl2N5O2: C, 59.51; H, 4.79; N, 14.46; found: C, 59.38; H, 4.60; N, 14.32. 1-(1-(2-chlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl)but-2-ynyl)-4-phenylpiperazine (8h) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as pale yellow solid (3.64 g, 81%); m. p, 197–199 °C. IR (KBr): 3100, 2951, 2192, 1682, 1559, 1441, 1350, 1134 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.44 (s, 3H, CH3), 2.70–2.71 (m, 4H, 2NCH2), 3.09–3.20 (m, 4H, 2PhNCH2), 4.79 (s, 2H, NCH2C≡C), 5.02 (s, 1H, NCH), 6.74–6.90 (m, 3H, aryl), 7.21–7.29 (m, 4H, aryl), 7.39–7.41 (m, 1H, aryl), 7.54–7.55 (m, 1H, aryl), 7.83 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.70, 26.93, 48.91, 49.85, 52.06, 83.19, 86.96, 114.32, 118.41, 126.61, 128.48, 128.80, 129.74, 130.37, 131.91, 134.44, 136.66, 138.22, 149.57, 151.76. MS (EI): m/z (%) = 449 (26.1) [M+]. Anal. Calc. for C24H24ClN5O2: C, 64.07; H, 5.38; N, 15.57; found: C, 64.29; H, 5.61; N, 15.72. 1-Benzyl-4-(4-(2-methyl-5-nitro-1H-imidazole-1-yl)-1-phenylbut-2-ynyl) piperazine (8i) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as creamy solid (3.99 g, 93%); m. p, 139–141 °C. IR (KBr): 3080, 2951, 2146, 1659, 1559, 1465, 1357 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.33–2.52 (complex, 11H, CH3, 2NCH2CH2N), 3.49 (s, 2H, NCH2Ph), 4.61 (s, 1H, NCH), 4.81 (s, 2H, NCH2C≡C), 7.16–7.45 (complex, 10H, aryl), 7.86 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 12.75, 25.65, 49.23, 51.42, 53.97, 60.85, 84.13, 88.88, 127.21, 128.48, 128.80, 131.91, 135.70, 138.22, 139.79, 151.76. MS (EI): m/z (%) = 429 (17.6) [M+]. Anal. Calc. for C25H27N5O2: C, 69.91; H, 6.34; N, 16.31; found: C, 69.76; H, 6.20; N, 16.14. 1-Benzyl-4-(1-(4-chlorophenyl)-4-(2-methyl-5-nitro-1H-imidazole-1-yl)but-2-ynyl)piperazine (8j) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as brown solid (4.22 g, 91%); m. p,171–173 °C. IR (KBr): 3041, 2930, 2152, 1679, 1553, 1470, 1361, 1169 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.33–2.48 (complex, 11H, CH3, 2NCH2CH2N), 3.44 (s, 2H, NCH2Ph), 4.62 (s, 1H, NCH), 4.82 (s, 2H, NCH2C≡C), 7.12–7.40 (complex, 9H, aryl), 7.85 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.07, 27.22, 49.23, 51.42, 53.32, 61.17, 83.51, 87.60, 127.21, 128.16, 128.48, 128.80, 130.37, 131.91, 132.87, 135.70, 138.22, 151.76. MS (EI): m/z (%) = 463 (24.7) [M+]. Anal. Calc. for C25H26ClN5O2: C, 64.72; H, 5.65; N, 15.09; found: C, 64.90; H, 5.81; N, 15.26. 1-Benzyl-4-(1-(2,4-dichlorophenyl)-4-(2-methyl-5-nitro-1Himidazole-1-yl)but-2-ynyl)piperazine (8k) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:2) afforded pure product as creamy solid (4.43 g, 89%); m. p, 113–115 °C. IR (KBr): 3079, 2938, 2149, 1654, 1558, 1460, 1353, 1129 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.34–2.54 (complex, 11H, CH3, 2NCH2CH2N), 3.48 (s, 2H, NCH2Ph), 4.79 (s, 2H, NCH2C≡C), 4.89 (s, 1H, NCH), 7.15–7.36 (m, 6H, aryl), 7.40–7.49 (m, 2H, aryl) 7.83 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 12.75, 26.28, 47.49, 49.85, 52.06, 60.25, 83.19, 85.72, 126.61, 127.21, 128.48, 128.80, 130.04, 131.60, 131.91, 134.12, 134.78, 135.70, 138.22, 151.76. MS (EI): m/z (%) = 497 (16.9) [M+]. Anal. Calc. for C25H25Cl2N5O2: C, 60.25; H, 5.06; N, 14.05; found: C, 60.39; H, 5.22; N, 14.19. 1-Benzyl-4-(1-(2-chlorophenyl)-4-(2-methyl-5-nitro-1Himidazole-1-yl)but-2-ynyl)piperazine (8l) Column Chromatography (SiO2) eluted with n-hexane: EtOAc (1:1) afforded pure product as creamy solid (3.85 g, 83%); m. p, 137–139 °C. IR (KBr): 3060, 2966, 2119, 1674, 1559, 1465, 1349, 1162 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 2.39–2.68 (complex, 11H, CH3, 2NCH2CH2N), 3.48 (s, 2H, NCH2Ph), 4.78 (s, 2H, NCH2C≡C), 4.97 (s, 1H, NCH), 7.11–7.29 (complex, 7H, aryl), 7.36–7.40 (m, 1H, aryl), 7.48–7.50 (m, 1H, aryl), 7.85 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.34, 26.88, 48.44, 49.06, 51.83, 60.44, 83.20, 86.58, 126.61, 127.24, 128.16, 128.46, 128.78, 129.03, 130.30, 131.85, 134.32, 135.55, 136.77, 138.33, 151.84. MS (EI): m/z (%) = 463 (19.5) [M+]. Anal. Calc. for C25H26ClN5O2: C, 64.72; H, 5.65; N, 15.09; found: C, 64.53; H, 5.49; N, 14.85. 4-Benzyl-1-(1-(4-chlorophenyl)-4-(2-methyl-5-nitro-1Himidazole- 1-yl) but-2-yn-1-yl) piperidine (8m) Column Chromatography (SiO2) eluted with n-hexane:EtOAc (5:2) afforded pure product as creamy solid (4.12 g, 89%); m. p, 124–126 °C. IR (KBr): 3100, 2959, 2163, 1659, 1563, 1480, 1355, 1165 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 1.36–1.69 (complex, 5H, CH2CHCH2), 1.95–1.97 (m, 1H, PhCHAHB), 2.26–2.27 (m, 1H, PhCHAHB), 2.39–2.57 (complex, 5H, NCH2, CH3), 2.82–2.86 (m, 2H, NCH2), 4.59 (s, 1H, NCH), 4.81 (s, 2H, NCH2C≡C), 7.02–7.41 (m, 9H, aryl), 7.86 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 12.91, 24.76, 26.69, 29.58, 40.11, 48.77, 55.84, 84.01, 87.87, 126.02, 128.21, 128.86, 130.48, 131.73, 132.70, 138.15, 138.80, 151.95. MS (EI): m/z (%) = 462 (25.3) [M+]. Anal. Calc. for C26H27ClN4O2: C, 67.45; H, 5.88; N, 12.10; found: C, 67.64; H, 6.07; N, 12.32. 4-Benzyl-1-(1-(2,4-dichlorophenyl)-4-(2-methyl-5-nitro-1Himidazole-1-yl) but-2-ynyl) piperidine (8n) Column Chromatography(SiO2) eluted with n-hexane:EtOAc (2:1) afforded pure product as creamy solid (4.17 g, 84%); m. p, 114–116 °C. IR (KBr): 3024, 2926, 2173, 1673, 1537, 1423, 1351, 1134 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 1.06–1.29 (m, 2H, CH2CH), 1.56–1.64 (complex, 3H, CH2CH), 2.00–2.07 (m, 1H, PhCHAHB), 2.15–2.23 (m, 1H, PhCHAHB), 2.40–2.50 (complex, 5H, NCH2, CH3), 2.73–2.84 (m, 2H, NCH2), 4.77 (s, 2H, NCH2C≡C), 4.85 (s, 1H, NCH), 7.09–7.28 (m, 7H, aryl), 7.39–7.45 (m, 1H, aryl), 7.82 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 12.91, 24.76, 26.69, 29.24, 40.11, 48.77, 50.70, 83.37, 85.94, 126.02, 126.96, 128.21, 128.86, 130.17, 131.73, 132.06, 134.32, 134.97, 135.59, 138.15, 138.80, 151.95. MS (EI): m/z (%) = 496 (27.4) [M+]. Anal. Calc. for C26H26Cl2N4O2: C, 62.78; H, 5.27; N, 11.26; found: C, 62.60; H, 5.07; N, 11.10. 4-Benzyl-1-(1-(2-chlorophenyl)-4-(2-methyl-5-nitro-1Himidazole-1-yl)but-2-yn-1-yl) piperidine (8o) Column Chromatography(SiO2) eluted with n-hexane:EtOAc (5:2) afforded pure product as white solid (3.75 g, 81%); m. p, 160–162 °C. IR (KBr): 3100, 2937, 2172, 1683, 1552, 1450, 1327, 1126 cm−1.1H NMR (CDCl3, 300 MHz) δppm = 1.46–1.63 (complex, 5H, CH2CHCH2), 2.05–2.08 (m, 1H, PhCHAHB), 2.20–2.23 (m, 1H, PhCHAHB), 2.39–2.50 (complex, 5H, NCH2, CH3), 2.83–2.87 (m, 2H, NCH2), 4.77 (s, 2H, NCH2C≡C), 4.93 (s, 1H, NCH), 7.09–7.28 (m, 7H, aryl), 7.39 (d, J = 8.1 Hz, 1H, aryl), 7.50 (d, J = 8.1 Hz, 1H, aryl), 7.83 (s, 1H, C(5)-H, imidazole). 13C NMR (CDCl3, 75 MHz) δppm = 13.27, 24.62, 26.89, 29.48, 40.50, 48.59, 51.50, 82.00, 86.21, 126.09, 126.73, 128.03, 128.46, 128.68, 130.31, 131.79, 134.20, 136.79, 138.09, 138.74, 151.70. MS (EI): m/z (%) = 463 (22.6) [M+]. Anal. Calc. for C25H26ClN5O2: C, 64.72; H, 5.65; N, 15.09; found: C, 64.95; H, 5.83; N, 15.30. Susceptibility profile of isolates According to the supplementary Tables S1, S2 and S3, among CP-E. coli and CP-K. pneumonia, all of them were resistant to amoxicillin/clavulanic acid, ampicillin/sulbactam, ticarcillin/clavulanic acid, cefazolin, ertapenem, cefuroxime and cefotaxime. However, lowest resistance was against nitrofurantoin (5/15 or 33% for CP-E. coli and 1/2 or 50% for CP-K. pneumonia), tigecycline (1/15 or 6.6% for CP-E. coli and 0% for CP-K. pneumonia) and polymyxin B (1/15 6.6% for CP-E. coli and 0% for CP-K. pneumonia). Additionally, 50% (1/2) of CP-K. pneumonia isolates were susceptible to amikacin. MSSA and MRSA isolates were resistant to penicillin, erythromycin and clindamycin, while both of them were susceptible to vancomycin, minocycle and linezolid. MSSA was also susceptible to rifampin, gentamicin, minocycline, sulfamethoxazole-trimethoprim (TMP-SMX) and levofloxacin. MRSA also exhibited resistance to TMP-SMX, levofloxacin and gentamicin and intermediate resistance to rifampin. The MIC and MBC determination The MIC and MBC levels of synthetic compounds against standard and clinical bacterial isolates has been depicted in Tables 4 and 5 and Figs. 2, 3, 4, 5, 6. Accordingly, the lowest MIC/MBC levels corresponded to compound 8g against standard S. aureus (1/2 µg/mL) and K. pneumonia (8/32 µg/mL) standard and clinical strains. Additionally, there was a significant difference between clinical and standard strains of E. coli regarding MIC and MBC levels of compounds 8h, 8k, 8l, 8n and 8o which exhibited lower levels against standard strain. Considering K. pneumonia, there was also a significant difference between clinical and standard strains for compounds 8b–8e, 8j, 8k and 8o. Compounds 8a–8e exerted higher antibacterial effects against clinical K. pneumonia and S. aureus compared to E. coli isolates. Compound 8i inferred low MIC and MBC (16 and 32 µg/mL, respectively) against E. coli. Interestingly, compounds 8i–8o conferred significant higher antibacterial effects against Gram-negative strains. Furthermore, there was no significant difference in MIC or MBC values between S. aureus standard strain and each of clinical MSSA/MRSA. The MIC of metronidazole against CP-E. coli, CP-K. pneumonia, MSSA and MRSA respectively ranged 32–64 µg/mL, 32–128 µg/mL, 16 µg/mL and 64 µg/mL. Additionally, metronidazole MBC levels against CP-E. coli, CP-K. pneumonia, MSSA and MRSA respectively ranged 32–128 µg/mL, 64–256 µg/mL, 32 µg/mL and 128 µg/mL. Acetic acid (0.5%) has no growth-inhibitory effect against bacterial isolates. Table 4The MIC and MBC concentrations of synthetic compounds against E. coli and K. pneumonia standard and clinical isolatesCompound/BacteriaE. coli S; MIC/MBC (µg/mL)E. coli C; MIC/MBC (µg/mL)K. pneumonia S; MIC/MBC (µg/mL)K. pneumonia C; MIC/MBC (µg/mL)p value8a32/12832/12816/6416/64> 0.058b32/12864/12864/12816/64*< 0.0018c32/12832/12832/12816/64*< 0.0018d32/12832/12832/12816/64*< 0.0018e32/6432/12832/12816/64*< 0.0018f32/128128/25632/6416/64< 0.0018g32/12832/1288/328/320.9988h16/6464/256*16/6416/64< 0.0018i16/3216/3216/6432/64> 0.058j16/6432/6432/12816/64*< 0.0018k16/6432/128*32/6464/128*< 0.0018l16/6432/128*16/6416/64< 0.0018m16/6416/6416/6416/64> 0.058n16/6432/128*32/12816/64*< 0.0018o16/6432/128*32/6416/64< 0.001Metronidazole8/1632/648/1664/128< 0.001E. coli S: Escherichia coli standard strain, E. coli C: carbapenemase-producing E. coli, K. pneumonia S: Klebsiella pneumonia standard strain, K. pneumonia C: carbapenemase-producing K. pneumonia, MIC: minimum inhibitory concentration, MBC: minimum bactericidal concentration, *indicating significant difference The MIC and MBC concentrations of synthetic compounds against E. coli and K. pneumonia standard and clinical isolates E. coli S: Escherichia coli standard strain, E. coli C: carbapenemase-producing E. coli, K. pneumonia S: Klebsiella pneumonia standard strain, K. pneumonia C: carbapenemase-producing K. pneumonia, MIC: minimum inhibitory concentration, MBC: minimum bactericidal concentration, *indicating significant difference Table 5The MIC and MBC concentrations of synthetic compounds against S. aureus standard and clinical isolatesCompound/BacteriaS. aureus S; MIC/MBC (µg/mL)MSSA; MIC/MBC (µg/mL)MRSA; MIC/MBC (µg/mL)p value8a32/12832/12832/128> 0.058b16/6416/6416/64> 0.058c16/6416/6416/64> 0.058d16/6416/6416/64> 0.058e16/6416/6416/64> 0.058f32/12832/12832/128> 0.058g1/21/21/2> 0.058h32/12832/12832/128> 0.058i64/25664/25664/256> 0.058j64/25664/25664/256> 0.058k64/25664/25664/256> 0.058l64/25664/25664/256> 0.058m64/25664/25664/256> 0.058n64/25664/25664/256> 0.058o64/25664/25664/256> 0.05Metronidazole4/816/3264/128< 0.0001 The MIC and MBC concentrations of synthetic compounds against S. aureus standard and clinical isolates MIC levels of nitroimidazole compounds against gram-negative bacteria in this study; E. coli S: Escherichia coli ATCC25922, K. pneumonia S: Klebsiella pneumonia ATCC13883. CP-E. coli: carbapenemase producer E. coli, CP-K. pneumonia: carbapenemase producer K. pneumonia. In comparison to metronidazole, against CP-E. coli, compounds 8i and 8m had significantly higher antibacterial effects (p < 0.001) and against CP-K. pneumonia, compounds 8a–8j and 8l–8o had significantly higher (p < 0.0001) antibacterial effects MBC levels of nitroimidazole compounds against gram-negative bacteria in this study; E. coli S: Escherichia coli ATCC25922, K. pneumonia S: Klebsiella pneumonia ATCC13883, CP-E. coli: carbapenemase producer E. coli, CP-K. pneumonia: carbapenemase producer K. pneumonia. Accordingly, compound 8g had significantly higher bactericidal effects than metronidazole against standard strain and CP-E. coli (p < 0.0001) MIC levels of nitroimidazole compounds against gram-positive bacteria in this study. Compound 8g exhibited significantly higher antibacterial effects against MSSA and compounds 8b (p < 0.001), 8c (p < 0.001), 8d (p < 0.001), 8e (p < 0.001) and 8g (p < 0.0001) exerted significantly higher antibacterial effects than metronidazole against MRSA. MRSA: methicillin-resistant Staphylococcus aureus, MSSA: methicillin-susceptible Staphylococcus aureus, NC: negative control MBC levels of nitroimidazole compounds against gram-positive bacteria in this study; MRSA: methicillin-resistant Staphylococcus aureus, MSSA: methicillin-susceptible Staphylococcus aureus The most potential antibacterial agents in this study with significant difference compared to metronidazole; CP-E. coli: carbapenemase producer E. coli, CP-K. pneumonia: carbapenemase producer K. pneumonia, MRSA: methicillin-resistant Staphylococcus aureus, MSSA: methicillin-susceptible Staphylococcus aureus Also, Fig. 6 depicts the significant lower MIC levels of synthetic compounds than metronidazole against bacterial isolates in this study. Structure–activity relationship From a structure–activity relationship (SAR) perspective, the synthesized nitroimidazole compounds can be categorized into three distinct groups based on their amine moieties. Additionally, considering the apparent biological activity of chloroaryl moieties in many established drugs, particularly concerning their antibacterial profiles, aryl residues were preferentially designed to include a chlorine group. In this context, the first group features morpholine residues (8a–8d), with all members demonstrating superior antibacterial effects compared to metronidazole, particularly against K. pneumonia (16/64 µg/mL). The second group consists of piperazine residues (8e–8h), which exhibited potent antibacterial activity against all tested bacteria; notably, compound 8g showed remarkable inhibitory effects against both standard and clinical strains of S. aureus (1/2 µg/mL) and K. pneumonia (8/32 µg/mL). The significant biological activity of this second family may be attributed to the presence of the piperazine moiety, known for its antibacterial properties. The third group contains compounds with a 4-phenylpiperazine moiety (8i–8o), which, similar to the second group, exhibited strong antibacterial activity against all tested bacteria. Among these, compounds 8j and 8m demonstrated enhanced activity against E. coli, while compounds 8j, 8l, 8m, 8n, and 8o outperformed metronidazole against K. pneumonia. Anti-biofilm effects The biofilm formation by the isolates without exposure to the compounds has been exhibited in Table 6. Accordingly, the mean OD490 value of the six control wells included 0.05. None of the isolates were strong biofilm producers. Seven clinical E. coli, both of the clinical K. pneumonia, and MSSA and MRSA isolates were moderate biofilm producers. One E. coli isolate was weak biofilm producer and eight of them were biofilm non-producers. Furthermore, the biofilm formation of those isolates treated with the synthetic compounds has been represented in Table 6. Accordingly, compounds 8c, 8f, 8g, 8i, 8n and 8o exhibited significant more potent anti-biofilm effects against clinical isolates. Moreover, moderate biofilm-producing E. coli isolates with higher OD values including E4, E10, E11 and E13 were able to produce biofilm when treated with compounds 8d, 8h, 8j and 8l. In addition, K. pneumonia K1 produced moderate biofilm in exposure to compounds 8b, 8d, 8j and 8l. MSSA biofilm formation was inhibited by all the compounds, while MRSA produced moderate biofilm in exposure to compounds 8i-8o (Table 7). Table 6The biofilm formation by untreated bacterial isolates in this studyIsolateMean ODNT Biofilm levelNC0.05Non-producerPC1.8StrongE10.071Non-producerE20.069Non-producerE30.060Non-producerE40.114ModerateE50.083WeakE60.059Non-producerE70.094ModerateE80.085ModerateE90.076Non-producerE100.167ModerateE110.122ModerateE120.061Non-producerE130.112ModerateE140.076Non-producerE150.084ModerateK10.138ModerateK20.091ModerateMSSA0.118ModerateMRSA0.099ModerateOD: optical density, NT: non-treated, E: E. coli, K: K. pneumonia, MSSA: methicillin-susceptible S. aureus, MRSA: methicillin-resistant S. aureus The biofilm formation by untreated bacterial isolates in this study OD: optical density, NT: non-treated, E: E. coli, K: K. pneumonia, MSSA: methicillin-susceptible S. aureus, MRSA: methicillin-resistant S. aureus Table 7Biofilm formation levels by treated isolatesIsolate8a8b8c8d8e8f8g8h8i8j8k8l8m8n8oNCNNNNNNNNNNNNNNNPCSSSSSSSSSSSSSSSE1NNNNNNNNNMNMNNNE2NNNMNNNNNNNNNNNE3NNNNMNNNNNNNNNNE4MNNNNNNMNMNMNNNE5NNNNNNNNNNNNNNNE6NNNNNNNNNNNNNNNE7NNNMNNNNNNNNNNNE8NNNNNNNNNNNMNNNE9NNNNNNNNNNNNNNNE10NNNMNNNMNMNNNNNE11NNNNNNNNNMNMNNNE12NNNNNNNNNNNNNNNE13NNNMNNNMNNNNNNNE14NNNNNNNNNNNNNNNE15NNNNNNNNNNNNNNNK1NMNMNNNNNMNMNNNK2NNNNNNNNNNNNNNNMSSANNNNNNNNNNNNNNNMRSANNNNNNNNMMMMMMME: E. coli, K: K. pneumonia, MSSA: methicillin-susceptible S. aureus, MRSA: methicillin-resistant S. aureus, NC: negative control, PC: positive control (biofilm producer S. aureus), S, N and M: strong, non-producer and moderate biofilm producer, respectively Biofilm formation levels by treated isolates E: E. coli, K: K. pneumonia, MSSA: methicillin-susceptible S. aureus, MRSA: methicillin-resistant S. aureus, NC: negative control, PC: positive control (biofilm producer S. aureus), S, N and M: strong, non-producer and moderate biofilm producer, respectively The in silico analyses Molecular dynamics simulation The Root Mean Square Deviation (RMSD) values were calculated for both PBP2a and its ligands in the complex state to track the movement of Cα and heavy atoms in the protein and ligand during MD simulation. The RMSD graph of PBP2a structure inferred consistent fluctuation throughout the simulation, with mean values of (0.34 ± 0.02) nm for metronidazole and (0.32 ± 0.02) nm for compound 8g, indicating the stability of PBP2a during simulation (Fig. 7A). Additionally, Root Mean Square Fluctuation (RMSF) values of PBP2a in the complex state were calculated to analyze local structural fluctuations, with high values observed in loop regions of the protein. This high flexibility had no negative impact neither on the ligand binding nor the overall stability of the PBP2a-ligand complexes, as shown in the RMSF plot which demonstrated consistent behavior of the PBP2a backbone in the presence of different ligands (Fig. 7B). For compounds at the catalytic site, RMSD values of 0.08 nm for metronidazole and 0.15 nm for compound 8g indicated their proper interactions to the catalytic site and suitable stability in complex structures. Notably, compound 8g exhibited higher flexibility compared to metronidazole, allowing for better exposure to catalytic site residues and facilitating interactions between residue side chains and the compound. A The RMSD of the Cα atoms changes during simulation time. B The RMSF of the Cα atoms along MD simulation. C The RMSD of the heavy atoms in the compound fluctuates during simulation time. The black and red colors are related to the PBP2a-metronidazole and PBP2a-compound 8g complexes, respectively Binding mode and free binding energy analyses During MD simulations, the values of ΔGbind, van der Waals energy (ΔEvdw), and electrostatic energy (ΔEele) components for complexes were obtained and are presented in Table 8. The MMPBSA method was employed to calculate the binding free energy and evaluate the energetic interactions of each compound with the binding landscape. For the complexes with metronidazole and compound 8g, the computed binding free energies were determined to be − 43.06 and − 75.16 kJ/mol, respectively. The range of van der Waals contributions (ΔEvdw) for the complexes varied from − 161.28 to − 84.12 kJ/mol, while the electrostatic contributions (ΔEele) for both ligands were approximately − 29.50 kJ/mol. The analysis of the free energy components indicated that ΔEvdw and ΔEele in the gas phase played a significant role in compound binding in the two complexes. On the other hand, solvation energies (ΔGGB) had a negative impact on the binding energies. The study demonstrated that hydrophobic or nonpolar interactions (ΔEnonpolar) were the primary driving force behind compound binding, while polar interactions (ΔEpolar) were unfavorable for binding at the PBP2a binding site, with contributions ranging from 50.00 to 105.45 kJ/mol. Compound 8g exhibited a lower ΔGbind compared to metronidazole, suggesting the establishment of strong contacts with binding pocket residues. These findings have significant implications for the rational design of potential therapeutic agents targeting PBP2a. The identification of compound 8g with superior binding affinities compared to the reference ligand opens up new possibilities for drug development. The detailed analysis of conformational stability, residue fluctuations, and binding energetics provides a solid framework for optimizing this compound and understanding its interactions with the target protein (Fig. 8). Table 8The contribution of various energy components in the ∆Gbind (kJ/mol)PBP2a-metronidazolePBP2a-compound 8g∆Eelea− 29.46 ± 3.53− 29.99 ± 3.04∆EvdWb− 84.12 ± 3.84− 161.28 ± 2.47∆GPBc79.46 ± 6.25135.44 ± 4.80∆GSAd− 9.30 ± 0.15− 19.42 ± 0.31∆Enon-polare− 93.42 ± 1.99− 180.7 ± 1.39∆Epolarf50.00 ± 4.89105.45 ± 3.92∆Gbind− 43.42 ± 3.44− 75.25 ± 2.78aElectrostatic connection, bvan der Waals connection, cPolar contribution of the solvation effect, dNon-polar contribution of solvation effect, e ∆Enon-polar = ∆EvdW + ∆GSA, f ∆Epolar = ∆Eele + ∆GGB The contribution of various energy components in the ∆Gbind (kJ/mol) aElectrostatic connection, bvan der Waals connection, cPolar contribution of the solvation effect, dNon-polar contribution of solvation effect, e ∆Enon-polar = ∆EvdW + ∆GSA, f ∆Epolar = ∆Eele + ∆GGB The PBP2a complex was studied using MD simulations to generate 2D and 3D zoom views. The complex included metronidazole (A and B) and compound 8g (C and D) as ligands. In the representation, PBP2a is shown as a light blue cartoon, with highlighted residues depicted as blue sticks. The ligands are shown as slate and wheat sticks. Hydrogen bonds are indicated by green dashed and blue lines, while red dots signify hydrophobic interactions. Spoked arcs illustrate nonbonded contacts between PBP2a residues and the ligands The ADMET properties of potential candidate compound 8g has been represented in supplementary Table 9. ADMET properties of 8gStatusMolecular weight338.411Number of hydrogen bond acceptors5Number of hydrogen bond donors0Number of rotational bonds4Partition coefficient in oil to water (CLogP)1.21Topological polar surface area(Å2)66.88Aqueous solubility descriptor(LogS)− 3.00AbsorptionCaco-2 cell permeability0.796Human intestinal absorption (HIA%)92.383Skin Permeability− 2.737P-glycoprotein substrateYesP-glycoprotein I inhibitorYesP-glycoprotein II inhibitorNoDistributionVolume of distribution0.594Barrier blood–brain permeability− 0.198Central nervous system permeability− 1.987MetabolismCytochrome P450 1A2 inhibitionNoCytochrome P450 2C19 inhibitionYesCytochrome P450 2C9 inhibitionNoCytochrome P450 2D6 inhibitionYesCytochrome P450 2D6 substrateNoCytochrome P450 3A4 inhibitionNoCytochrome P450 3A4 substrateYesExcretionTotal renal clearance0.418Renal OCT2 substrateYesToxicityHuman ether related gene_inhibition INoOral rat acute toxicity (LD50)2.134Oral rat chronic toxicity (LOAEL)1.539Skin sensitizationNo Discussion In this study, propargylamine compounds (8a–8o) were synthesized by the A3 coupling reaction of sample substrates in the presence of CDSCS. These compounds with alkynyl group have considerable potential in medicinal chemistry for drug discovery [61, 62]. The antibacterial effects of these compounds demonstrated that the lowest MIC/MBC levels corresponded to compound 8g against standard S. aureus (1/2 µg/mL) and K. pneumonia (8/32 µg/mL) standard and clinical strains. The in silico analyses confirmed the strong and stable binding of the compound 8g to the active site of PBP2a of MRSA. This was comparable to those of metronidazole being 32–128 µg/mL against K. pneumonia and 32–64 µg/mL against S. aureus. Additionally, E. coli (with higher susceptibility of standard strains) strains were more susceptible to compounds 8h, 8k, 8l, 8n and 8o with lower MIC and MBC levels. Comparably, MIC levels of metronidazole against E. coli ranged 16–64 µg/mL. Moreover, standard strains of K. pneumonia were more susceptible to compounds 8b–8e, 8j, 8k and 8o. Compounds 8a–8e exerted higher antibacterial effects against clinical K. pneumonia and S. aureus. Interestingly, compounds 8i–8o conferred significant higher antibacterial effects against Gram-negative strains. Furthermore, there was no significant difference in MIC or MBC values between S. aureus standard strain and each of clinical MSSA/MRSA. A lead thiazole compound could inhibit the growth of MRSA at 1.3 µg/mL in vivo and was non-toxic at up to 20 µg/mL [63]. Another metronidazole-triazole hybrids have depicted anti-MRSA effects at 4 µg/mL which was decreased to 1 µg/mL in combination to oxacillin at 1:1 ratio [64]. In a study, a series of synthetic small molecules demonstrated the eradication of MRSA rapidly at low and non-toxic levels (MIC of 3.125–6.25 μg/ml) [65]. In a study, synthetic biphenylthiazoles MIC against MRSA included 0.39 to 25 μg/mL [66]. MHY1383 synthetic compound has inferred antibacterial and anti-biofilm effects at low concentrations against P. aeruginosa, E. coli, Bacillus subtilis and S. aureus respectively at 1–10 pM, 1 pM, 1 nM, and 10 nM [67]. Pyrazole and Diene dione (Q1, M3 and Q7) compounds have deciphered antibacterial effects against Enterococcus faecalis, Proteus mirabilis and S. aureus at 0.312 mg/mL, 1.25 mg/mL and 0.156 mg/mL, respectively [68]. In this study, compound 8g exhibited substantially low MIC and MBC levels against MSSA, MRSA and CR-K. pneumonia isolates. One aspect of selection of a proper antibacterial compound includes the evaluation of non-toxicity on normal cells. Some of studies have the limitation in this regard. We previously determined these compounds inhibitory effects against anaerobic parasite giardiasis which interacted to the DNA [44]. Indeed, nitro group of imidazole-based drugs can interact with biological nucleophiles (amino acids, nucleic acids and enzymes) and membrane permeabilization affecting multiple aspects of bacterial cell growth and function [64, 69]. Herein, the binding ability of compound 8g to PBP2a was determined in silico which highlights cell wall synthesis inhibition, whereas its binding ability to the DNA is inevitable. Our synthetic compounds have three classes including Morpholine, Piperazine and Phenylpiperazine moieties with potent antibacterial activity. Morpholine derivatives have exerted low cytotoxicity (10 µM) against WI-38 normal fibroblast cells [70, 71]. Moreover, Piperazine derivatives have inferred low cytotoxicity on human normal cells [72, 73]. Similar results have been demonstrated regarding Phenylpiperazine derivatives with low cytotoxicity against normal cells [74–76]. The considerable limitations of our study also included low number of drug-resistant bacterial isolates and lack of in vivo study and evaluation of molecular mechanisms underlying the bacterial killing by these novel compounds. Future studies can focus on these limitations and assessment of combination therapy to lower the costs, antibiotic resistance and side effects [77, 78]. Conclusion Our study revealed that the nitroimidazole compounds 8a–8o exerted disparate antibacterial and anti-biofilm effects, most potent of which was compound 8g with lowest MIC and MBC levels against MSSA, MRSA and K. pneumonia. The findings were acceptable compared to the MIC and MBC levels of the reference antibiotic. Additionally, the in silico analyses confirmed the strong and stable binding of the compound 8g to the active site of PBP2a of MRSA. Considering the promising inhibitory and killing effects of these synthesized compounds against drug-resistant bacterial pathogens, further assessments is warranted to verify their properties in vivo and clinical trials and their synergistic effects with antibiotics in future. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements Not applicable. Author contributions E.Z. and A.G. conceptualized the study. E. Z. E. B. R. K. M. M. S.B. A.G. M.N.S.R. wrote the draft. E. Z. S.B, A. G. M.N. and S.R. performed the work. E.B. performed the in silico analyses. All authors reviewed the study. Funding This study was supported by Noncommunicable Diseases Research Center, Fasa University of Medical Sciences [Ethical code: IR.FUMS.REC.1402.057]. Data availability Data is provided within the manuscript or supplementary information files. Declarations Consent for publication All authors give consent for the publication of the manuscript in the Journal of BMC Chemistry. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement Data is provided within the manuscript or supplementary information files.